Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
Summary
The Publisher's Medical Devices sector report, “Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Reasons to Buy
The report enables you to:
Summary
The Publisher's Medical Devices sector report, “Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by the Publisher's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1.1 List of Tables1.2 List of Figures
2 Introduction
2.1 Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Overview
3 Products under Development
3.1 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Territory
3.3 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Estimated Approval Date
3.5 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Ongoing Clinical Trials
4 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development
5 Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Companies and Product Overview
5.1 Abreos Biosciences Inc Company Overview
5.1.1 Abreos Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Acetaminophen Toxicity Diagnostics, LLC Company Overview
5.2.1 Acetaminophen Toxicity Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.3 Affinergy LLC Company Overview
5.3.1 Affinergy LLC Pipeline Products & Ongoing Clinical Trials Overview
5.4 Am Biotechnologies, LLC Company Overview
5.4.1 Am Biotechnologies, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.5 Analyticon Biotechnologies AG Company Overview
5.5.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
5.6 AnaZyme, LLC Company Overview
5.6.1 AnaZyme, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.7 Angle Biosciences Inc Company Overview
5.7.1 Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Atonomics A/S Company Overview
5.8.1 Atonomics A/S Pipeline Products & Ongoing Clinical Trials Overview
5.9 Augurix SA Company Overview
5.9.1 Augurix SA Pipeline Products & Ongoing Clinical Trials Overview
5.10 Baebies Inc Company Overview
5.10.1 Baebies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 Biocross SL Company Overview
5.11.1 Biocross SL Pipeline Products & Ongoing Clinical Trials Overview
5.12 Bioftalmik Applied Research Company Overview
5.12.1 Bioftalmik Applied Research Pipeline Products & Ongoing Clinical Trials Overview
5.13 BioMedomics Inc Company Overview
5.13.1 BioMedomics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.14 Biotech Resources Pty Ltd Company Overview
5.14.1 Biotech Resources Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.15 Burnet Institute Company Overview
5.15.1 Burnet Institute Pipeline Products & Ongoing Clinical Trials Overview
5.16 Carclo Diagnostic Solutions Ltd Company Overview
5.16.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.17 CardioGenics Inc Company Overview
5.17.1 CardioGenics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.18 Cellex Inc. Company Overview
5.18.1 Cellex Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.19 Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina Company Overview
5.19.1 Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina Pipeline Products & Ongoing Clinical Trials Overview
5.20 Claremont BioSolutions Company Overview
5.20.1 Claremont BioSolutions Pipeline Products & Ongoing Clinical Trials Overview
5.21 Columbia University Company Overview
5.21.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
5.22 CTK Biotech, Inc. Company Overview
5.22.1 CTK Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.23 DiaSys Diagnostic Systems GmbH Company Overview
5.23.1 DiaSys Diagnostic Systems GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.24 Edan Instruments Inc Company Overview
5.24.1 Edan Instruments Inc Pipeline Products & Ongoing Clinical Trials Overview
5.25 Enesi Pharma Ltd Company Overview
5.25.1 Enesi Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.26 Enigma Diagnostics Ltd (Inactive) Company Overview
5.26.1 Enigma Diagnostics Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.27 Erytech Pharma SA Company Overview
5.27.1 Erytech Pharma SA Pipeline Products & Ongoing Clinical Trials Overview
5.28 FK-Biotecnologia SA Company Overview
5.28.1 FK-Biotecnologia SA Pipeline Products & Ongoing Clinical Trials Overview
5.29 Foundation for Innovative New Diagnostics Company Overview
5.29.1 Foundation for Innovative New Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.30 Gendiag Company Overview
5.30.1 Gendiag Pipeline Products & Ongoing Clinical Trials Overview
5.31 Group K Diagnostics Company Overview
5.31.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.32 Instrumentation Laboratory Co Company Overview
5.32.1 Instrumentation Laboratory Co Pipeline Products & Ongoing Clinical Trials Overview
5.33 Integrated Diagnostics Inc (Inactive) Company Overview
5.33.1 Integrated Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.34 IntraMed Diagnostics, LLC Company Overview
5.34.1 IntraMed Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.35 IPI Singapore Company Overview
5.35.1 IPI Singapore Pipeline Products & Ongoing Clinical Trials Overview
5.36 Iron Horse Diagnostics, Inc. Company Overview
5.36.1 Iron Horse Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.37 Kenyatta University Company Overview
5.37.1 Kenyatta University Pipeline Products & Ongoing Clinical Trials Overview
5.38 Massachusetts Institute of Technology Company Overview
5.38.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
5.39 Medical University of South Carolina Company Overview
5.39.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview
5.40 Monash University Company Overview
5.40.1 Monash University Pipeline Products & Ongoing Clinical Trials Overview
5.41 Montana State University Company Overview
5.41.1 Montana State University Pipeline Products & Ongoing Clinical Trials Overview
5.42 NanoSpeed Diagnostics Inc Company Overview
5.42.1 NanoSpeed Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.43 Novartis AG Company Overview
5.43.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
5.44 Oasis Diagnostics Corp Company Overview
5.44.1 Oasis Diagnostics Corp Pipeline Products & Ongoing Clinical Trials Overview
5.45 Ohmx Corp Company Overview
5.45.1 Ohmx Corp Pipeline Products & Ongoing Clinical Trials Overview
5.46 OPKO Health Inc Company Overview
5.46.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
5.47 Oxford Immunotec Ltd Company Overview
5.47.1 Oxford Immunotec Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.48 P2D Inc Company Overview
5.48.1 P2D Inc Pipeline Products & Ongoing Clinical Trials Overview
5.49 Philips Healthcare Company Overview
5.49.1 Philips Healthcare Pipeline Products & Ongoing Clinical Trials Overview
5.50 Pop Test LLC Company Overview
5.50.1 Pop Test LLC Pipeline Products & Ongoing Clinical Trials Overview
5.51 PortaScience Inc Company Overview
5.51.1 PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview
5.52 Quidel Corp Company Overview
5.52.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview
5.53 SaltCheck Inc (Inactive) Company Overview
5.53.1 SaltCheck Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.54 Seattle Children's Hospital Company Overview
5.54.1 Seattle Children's Hospital Pipeline Products & Ongoing Clinical Trials Overview
5.55 SenGenix Inc Company Overview
5.55.1 SenGenix Inc Pipeline Products & Ongoing Clinical Trials Overview
5.56 SuperNova Diagnostics, Inc. Company Overview
5.56.1 SuperNova Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.57 Systagenix Wound Management Ltd Company Overview
5.57.1 Systagenix Wound Management Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.58 The University of New South Wales press Limited Company Overview
5.58.1 The University of New South Wales press Limited Pipeline Products & Ongoing Clinical Trials Overview
5.59 Thermo Fisher Scientific Inc Company Overview
5.59.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview
5.60 Trivitron Healthcare Pvt Ltd Company Overview
5.60.1 Trivitron Healthcare Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.61 True Diagnostics Inc Company Overview
5.61.1 True Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.62 Universal Biosensors Inc Company Overview
5.62.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview
5.63 University College Cork Company Overview
5.63.1 University College Cork Pipeline Products & Ongoing Clinical Trials Overview
5.64 University of Edinburgh Company Overview
5.64.1 University of Edinburgh Pipeline Products & Ongoing Clinical Trials Overview
5.65 University of South Australia Company Overview
5.65.1 University of South Australia Pipeline Products & Ongoing Clinical Trials Overview
5.66 Wellstat Diagnostics LLC Company Overview
5.66.1 Wellstat Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview
6 Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Recent Developments
6.1 Nov 12, 2019: VolitionRx announces third quarter 2019 financial results and business update
6.2 Nov 07, 2019: Celcuity reports third quarter 2019 financial results
6.3 Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI
6.4 Nov 05, 2019: BD announces results for 2019 fourth fiscal quarter and full year; provides fiscal 2020 guidance
6.5 Nov 05, 2019: OPKO Health reports 2019 third quarter business highlights and financial results
6.6 Oct 31, 2019: Cesca Therapeutics to change name and ticker symbol to reflect new strategic focus
6.7 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results
6.8 Oct 31, 2019: Surmodics reports fourth quarter fiscal 2019 results and issues fiscal 2020 revenue and EPS Guidance
6.9 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results.
6.10 Oct 30, 2019: Quidel reports third quarter 2019 financial results
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact Us
7.4 Disclaimer
List of Tables
Table 1: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Territory
Table 3: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Ongoing Clinical Trials
Table 6: Clinical Chemistry Rapid Tests & Point of Care (POC) Diagnostic Tests Companies - Pipeline Products by Stage of Development
Table 7: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development
Table 8: Abreos Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Veritope ELISA Based Immunoassay - Natalizumab - Product Status
Table 10: Veritope ELISA Based Immunoassay - Natalizumab - Product Description
Table 11: Veritope Immunoassay - Atezolizumab - Product Status
Table 12: Veritope Immunoassay - Atezolizumab - Product Description
Table 13: Veritope Immunoassay - Daratumumab - Product Status
Table 14: Veritope Immunoassay - Daratumumab - Product Description
Table 15: Veritope Immunoassay - Eculizumab - Product Status
Table 16: Veritope Immunoassay - Eculizumab - Product Description
Table 17: Veritope Immunoassay - Pertuzumab - Product Status
Table 18: Veritope Immunoassay - Pertuzumab - Product Description
Table 19: Veritope Immunoassay - Ramucirumab - Product Status
Table 20: Veritope Immunoassay - Ramucirumab - Product Description
Table 21: Veritope Immunoassay - Tocilizumab - Product Status
Table 22: Veritope Immunoassay - Tocilizumab - Product Description
Table 23: Veritope Immunoassay - Vedolizumab - Product Status
Table 24: Veritope Immunoassay - Vedolizumab - Product Description
Table 25: Veritope Lateral Flow Immunoassay - Adalimumab - Product Status
Table 26: Veritope Lateral Flow Immunoassay - Adalimumab - Product Description
Table 27: Veritope Lateral Flow Immunoassay - Alemtuzumab - Product Status
Table 28: Veritope Lateral Flow Immunoassay - Alemtuzumab - Product Description
Table 29: Veritope Lateral Flow Immunoassay - Bevacizumab - Product Status
Table 30: Veritope Lateral Flow Immunoassay - Bevacizumab - Product Description
Table 31: Veritope Lateral Flow Immunoassay - Cetuximab - Product Status
Table 32: Veritope Lateral Flow Immunoassay - Cetuximab - Product Description
Table 33: Veritope Lateral Flow Immunoassay - Infliximab - Product Status
Table 34: Veritope Lateral Flow Immunoassay - Infliximab - Product Description
Table 35: Veritope Lateral Flow Immunoassay - Ipilimumab - Product Status
Table 36: Veritope Lateral Flow Immunoassay - Ipilimumab - Product Description
Table 37: Veritope Lateral Flow Immunoassay - Nivolumab - Product Status
Table 38: Veritope Lateral Flow Immunoassay - Nivolumab - Product Description
Table 39: Veritope Lateral Flow Immunoassay - Obinutuzumab - Product Status
Table 40: Veritope Lateral Flow Immunoassay - Obinutuzumab - Product Description
Table 41: Veritope Lateral Flow Immunoassay - Pembrolizumab - Product Status
Table 42: Veritope Lateral Flow Immunoassay - Pembrolizumab - Product Description
Table 43: Veritope Lateral Flow Immunoassay - Rituximab - Product Status
Table 44: Veritope Lateral Flow Immunoassay - Rituximab - Product Description
Table 45: Veritope Lateral Flow Immunoassay - Trastuzumab - Product Status
Table 46: Veritope Lateral Flow Immunoassay - Trastuzumab - Product Description
Table 47: Acetaminophen Toxicity Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 48: AcetaSTAT(r) - Product Status
Table 49: AcetaSTAT(r) - Product Description
Table 50: Affinergy LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 51: Phagelock Assay - Product Status
Table 52: Phagelock Assay - Product Description
Table 53: Am Biotechnologies, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 54: Thioaptamer Diagnostic System - sALP Biomarker - Product Status
Table 55: Thioaptamer Diagnostic System - sALP Biomarker - Product Description
Table 56: Thioaptamers Diagnostic System - Gpx Biomarker - Product Status
Table 57: Thioaptamers Diagnostic System - Gpx Biomarker - Product Description
Table 58: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
Table 59: RFslide Latex Slide Test - Product Status
Table 60: RFslide Latex Slide Test - Product Description
List of Figures
Figure 1: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Territory
Figure 3: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Regulatory Path
Figure 4: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Pipeline Products by Estimated Approval Date
Figure 5: Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Ongoing Clinical Trials
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abreos Biosciences Inc
- Acetaminophen Toxicity Diagnostics, LLC
- Affinergy LLC
- Am Biotechnologies, LLC
- Analyticon Biotechnologies AG
- AnaZyme, LLC
- Angle Biosciences Inc
- Atonomics A/S
- Augurix SA
- Baebies Inc
- Biocross SL
- Bioftalmik Applied Research
- BioMedomics Inc
- Biotech Resources Pty Ltd
- Burnet Institute
- Carclo Diagnostic Solutions Ltd
- CardioGenics Inc
- Cellex Inc.
- Claremont BioSolutions
- Columbia University
- CTK Biotech, Inc.
- DiaSys Diagnostic Systems GmbH
- Edan Instruments Inc
- Enesi Pharma Ltd
- Erytech Pharma SA
- FK-Biotecnologia SA
- Foundation for Innovative New Diagnostics
- Gendiag
- Group K Diagnostics
- Instrumentation Laboratory Co
- IntraMed Diagnostics, LLC
- IPI Singapore
- Iron Horse Diagnostics, Inc.
- Kenyatta University
- Massachusetts Institute of Technology
- Medical University of South Carolina
- Monash University
- Montana State University
- NanoSpeed Diagnostics Inc
- Novartis AG
- Oasis Diagnostics Corp
- Ohmx Corp
- OPKO Health Inc
- Oxford Immunotec Ltd
- P2D Inc
- Philips Healthcare
- Pop Test LLC
- PortaScience Inc
- Quidel Corp
- Seattle Children's Hospital
- SenGenix Inc
- SuperNova Diagnostics, Inc.
- Systagenix Wound Management Ltd
- The University of New South Wales press Limited
- Thermo Fisher Scientific Inc
- Trivitron Healthcare Pvt Ltd
- True Diagnostics Inc
- Universal Biosensors Inc
- University College Cork
- University of Edinburgh
- University of South Australia
- Wellstat Diagnostics LLC
![In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image](http://www.researchandmarkets.com/product_images/12002/12002788_60px_jpg/invitro_diagnostics_market.jpg)
